Axios @axios
Aduhelm, the Alzheimer's treatment controversially approved by the FDA, won't just put Medicare's budget in peril. The $56,000-per-year drug could single-handedly represent one percentage point of all health care spending by next year. https://t.co/hLV0yiTUoi — PolitiTweet.org
